Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Huber · SciRah

Researcher profile · Semantic Scholar

R. Huber

Share profile

R. Huber — researcher profile on SciRah

h-index: 42
Works: 325
Citations: 12K

Most-cited papers

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
Dong-Wan Kim, M. Tiseo, M. Ahn, K. Reckamp +16 more
2017Journal of Clinical Oncology515 citations Open access
Semantic Scholar
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC
C. Manegold, A. Dingemans, J. Gray, K. Nakagawa +23 more
2017Journal of Thoracic Oncology224 citations Open access
Semantic Scholar
Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy
J. Leipe, L. Christ, A. Arnoldi, Erik Mille +9 more
2018RMD Open91 citations Open access
Semantic Scholar
Screening for lung cancer in individuals who never smoked: An IASLC Early Detection and Screening Committee Report.
A. Kerpel-Fronius, M. Tammemagi, M. Čavić, C. Henschke +7 more
2021Journal of Thoracic Oncology81 citations Open access
Semantic Scholar
Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study
M. Thomas, S. Ponce-Aix, A. Navarro, J. Riera-Knorrenschild +33 more
2018Annals of Oncology76 citations Open access
Semantic Scholar
SCLC-State of the Art and What Does the Future Have in Store?
K. Kahnert, D. Kauffmann-Guerrero, R. Huber
2016Clinical Lung Cancer70 citations
Semantic Scholar
Interdisciplinary multimodality management of stage III nonsmall cell lung cancer
R. Huber, D. D. De Ruysscher, H. Hoffmann, S. Reu +1 more
2019European Respiratory Review66 citations Open access
Semantic Scholar
Targeted Natural Killer Cell–Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial
G. Multhoff, Sophie Seier, S. Stangl, W. Sievert +21 more
2020Clinical Cancer Research59 citations Open access
Semantic Scholar
Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort
K. Kahnert, Tanja Lucke, R. Huber, J. Behr +14 more
2017PLoS ONE50 citations Open access
Semantic Scholar
Black and Blue
D. Kauffmann-Guerrero, K. Kahnert, S. Pratschke, M. Angstwurm +2 more
2017Respiration47 citations
Semantic Scholar
Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach
K. Kahnert, P. Alter, T. Welte, R. Huber +6 more
2018Respiratory Research45 citations Open access
Semantic Scholar
Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations
D. Kauffmann-Guerrero, A. Tufman, K. Kahnert, B. Bollmann +6 more
2020Oncology Research and Treatment33 citations
Semantic Scholar
Effectiveness of a specialised breathlessness service for patients with advanced disease in Germany: a pragmatic fast-track randomised controlled trial (BreathEase)
M. Schunk, L. Le, Z. Syunyaeva, B. Haberland +13 more
2021European Respiratory Journal29 citations Open access
Semantic Scholar
Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs
W. Brückl, Amanda Tufman, R. Huber
2017Expert Review of Anticancer Therapy28 citations
Semantic Scholar
NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy
D. Kauffmann-Guerrero, R. Huber, S. Reu, A. Tufman +4 more
2017Respiration26 citations Open access
Semantic Scholar
Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer
D. Kauffmann-Guerrero, K. Kahnert, R. Huber
2020Drugs25 citations Open access
Semantic Scholar
Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer
O. Roengvoraphoj, C. Wijaya, C. Eze, Ming-Lun Li +6 more
2017Strahlentherapie und Onkologie (Print)25 citations
Semantic Scholar
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial.
S. Peters, D. D. De Ruysscher, U. Dafni, E. Felip +15 more
201823 citations
Semantic Scholar
Interleukin-22 is elevated in lavage from patients with lung cancer and other pulmonary diseases
Amanda Tufman, R. Huber, S. Völk, F. Aigner +8 more
2016BMC Cancer20 citations Open access
Semantic Scholar
New developments in locally advanced nonsmall cell lung cancer
R. Huber, D. Kauffmann-Guerrero, H. Hoffmann, M. Flentje
2021European Respiratory Review19 citations Open access
Semantic Scholar
OA 05.05 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial
M. Ahn, D. Camidge, M. Tiseo, K. Reckamp +15 more
201718 citations Open access
Semantic Scholar
Guideline adherence of tumor board recommendations in lung cancer and transfer into clinical practice
J. Walter, C. Moeller, B. Resuli, D. Kauffmann-Guerrero +7 more
2023Journal of Cancer Research and Clinical Oncology17 citations Open access
Semantic Scholar
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
S. Gettinger, R. Huber, Dong-Wan Kim, L. Bazhenova +18 more
2022JTO Clinical and Research Reports17 citations Open access
Semantic Scholar
Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort
K. Kahnert, Tanja Lucke, F. Biertz, Andreas Lechner +13 more
2017Respiratory Research17 citations Open access
Semantic Scholar
Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status.
S. Gettinger, Sen Zhang, J. Hodgson, L. Bazhenova +15 more
201617 citations
Semantic Scholar
Lung Cancer Screening Considerations During Respiratory Infection Outbreaks, Epidemics or Pandemics: An International Association for the Study of Lung Cancer Early Detection and Screening Committee Report
R. Huber, M. Čavić, A. Kerpel-Fronius, L. Viola +14 more
2021Journal of Thoracic Oncology16 citations Open access
Semantic Scholar
Relationship of spirometric, body plethysmographic, and diffusing capacity parameters to emphysema scores derived from CT scans
K. Kahnert, B. Jobst, F. Biertz, J. Biederer +8 more
2018Chronic Respiratory Disease15 citations Open access
Semantic Scholar
How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience
O. Roengvoraphoj, C. Eze, C. Wijaya, M. Dantes +6 more
2018European Journal of Nuclear Medicine and Molecular Imaging14 citations
Semantic Scholar
Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT).
A. Tufman, J. Neumann, F. Manapov, L. Sellmer +12 more
2021Lung Cancer13 citations
Semantic Scholar
Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin
D. Kauffmann-Guerrero, R. Huber
2020Lung Cancer13 citations Open access
Semantic Scholar
Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?
M. Reck, K. Kerr, C. Grohé, C. Manegold +9 more
2019Future Oncology13 citations Open access
Semantic Scholar
Management of Progressive Pulmonary Nodules Found during and outside of CT Lung Cancer Screening Studies
M. Meyer, R. Vliegenthart, T. Henzler, D. Buergy +25 more
2017Journal of Thoracic Oncology13 citations Open access
Semantic Scholar
P3.02a-013 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial: Topic: ALK Clinical
D. Camidge, M. Tiseo, M. Ahn, K. Reckamp +17 more
201713 citations Open access
Semantic Scholar
Perception of climate change in patients with chronic lung disease
J. Götschke, P. Mertsch, Michael Bischof, N. Kneidinger +9 more
2017Pneumologie12 citations Open access
Semantic Scholar
Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives
S. Wessels, T. Muley, P. Christopoulos, M. Meister +16 more
2020Translational Lung Cancer Research11 citations Open access
Semantic Scholar
Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib
D. Kauffmann-Guerrero, K. Kahnert, J. Kumbrink, Z. Syunyaeva +2 more
2019Clinical Lung Cancer11 citations
Semantic Scholar
Tracheobronchial stents in mucopolysaccharidosis.
R. Karl, Schoenknecht Carola, Ensenauer Regina, Nicola Thomas +1 more
2016International Journal of Pediatric Otorhinolaryngology11 citations
Semantic Scholar
Hedgehog Pathway Activation Might Mediate Pemetrexed Resistance in NSCLC Cells
Yichao Liu, R. Huber, R. Kiefl, Amanda Tufman +1 more
2020Anticancer Research9 citations Open access
Semantic Scholar
Assessment of lung function in a large cohort of patients with acromegaly.
S. Störmann, B. Gutt, J. Roemmler-Zehrer, M. Bidlingmaier +3 more
2017European Journal of Endocrinology9 citations Open access
Semantic Scholar
Frequency and clinical relevance of EGFR mutations and EML4–ALK translocations in octogenarians with non-small cell lung cancer
A. Tufman, K. Kahnert, T. Duell, D. Kauffmann-Guerrero +6 more
2017OncoTargets and Therapy9 citations Open access
Semantic Scholar
OA08.06 Brigatinib Activity in Patients with ALK+ NSCLC and Intracranial CNS Metastases in Two Clinical Trials
S. Gettinger, Dong-Wan Kim, M. Tiseo, C. Langer +15 more
20179 citations Open access
Semantic Scholar
Role of the erythropoietin receptor in Lung Cancer cells: erythropoietin exhibits angiogenic potential
Xiao-Qing Liu, Amanda Tufman, J. Behr, R. Kiefl +2 more
2020Journal of Cancer8 citations Open access
Semantic Scholar
Identification of lung adenocarcinoma-specific exosome RNAs in peripheral blood by RNA-Seq analysis.
X.-Q. Liu, A. Tufman, R. Kiefl, G.-F. Li +2 more
2020European Review for Medical and Pharmacological Sciences8 citations
Semantic Scholar
Dermal Filler Injections Mimic Tumor Activity during Immune Checkpoint Inhibition
Z. Syunyaeva, K. Kahnert, D. Kauffmann-Guerrero, R. Huber +1 more
2018Respiration8 citations
Semantic Scholar
Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries
A. Rich, D. Baldwin, I. Alfageme, P. Beckett +37 more
2018BMC Cancer8 citations Open access
Semantic Scholar
Disease-specific medication, patient-reported diagnoses and their relation to COPD severity for common comorbidities in COPD
Tanja Lucke, Ronald Herrera, M. Wacker, R. Holle +9 more
20177 citations
Semantic Scholar
SHERLOC: A phase 2 study of MM-121 plus with docetaxel versus docetaxel alone in patients with heregulin (HRG) positive advanced non-small cell lung cancer (NSCLC).
L. Sequist, P. Janne, R. Huber, J. Gray +9 more
2019Journal of Clinical Oncology6 citations
Semantic Scholar
Less radiation, same quality: contrast-enhanced multi-detector computed tomography investigation of thoracic lymph nodes with one milli-sievert
U. Mueller-Lisse, Larissa Marwitz, Amanda Tufman, R. Huber +4 more
2018La radiologia medica6 citations
Semantic Scholar
1527OTop-line data from the randomized phase 2 IMPULSE study in small-cell lung cancer (SCLC): Immunotherapeutic maintenance treatment with lefitolimod
M. Thomas, S. Ponce-Aix, A. N. Mendivil, J. R. Knorrenschild +9 more
20176 citations Open access
Semantic Scholar
Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial.
M. Ahn, D. Camidge, M. Tiseo, K. Reckamp +15 more
20176 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Kauffmann-Guerrero×14
Invite
D. Kauffmann-Guerrero — researcher profile on SciRah
K. Kahnert×10
Invite
K. Kahnert — researcher profile on SciRah
M. Ahn×7
Invite
M. Ahn — researcher profile on SciRah
S. Gettinger×7
Invite
S. Gettinger — researcher profile on SciRah

×7

Invite

C. Langer — researcher profile on SciRah

Invite

D. Camidge — researcher profile on SciRah

Dong-Wan Kim×6

Invite

Dong-Wan Kim — researcher profile on SciRah

Invite

M. Tiseo — researcher profile on SciRah

Invite

H. West — researcher profile on SciRah

W. Reichmann×6

Invite

W. Reichmann — researcher profile on SciRah

Invite

D. Kerstein — researcher profile on SciRah

Amanda Tufman×6

Invite

Amanda Tufman — researcher profile on SciRah